A New Model Based on 25-Hydroxyvitamin D3 for Predicting Active Crohn’s Disease in Chinese Patients

Lin, Sinan; Wang, Ying; Li, Li; Chen, Peng; Mao, Ren; Feng, Rui; Qiu, Yun; He, Yao; Chen, Baili; Zeng, Zhirong; Chen, Minhu; Zhang, Shenghong

doi:10.1155/2018/3275025

Cited by 9 publications

(5 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD patients show high prevalence of vitamin D deficiency and have significantly lower vitamin D levels than do patients with irritable bowel syndrome (169). Serum vitamin D level is negatively correlated with disease activity in CD patients (170). Patients with a low vitamin D level (<30 ng/ml) are more likely to stop anti-TNF therapy early owing to a loss of response (HR = 3.49, 95% CI: 1.34-9.09) (68).…”

Section: Vitamin Dmentioning

confidence: 99%

Serum Biomarkers for Inflammatory Bowel Disease

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is a chronic, inflammatory disorder of the gastrointestinal tract. As the novel therapeutic goal and biologicals are widely recognized, accurate assessment of disease and prediction of therapeutic response have become a crucial challenge in clinical practice. Also, because of the continuously rising incidence, convenient and economical methods of diagnosis and clinical assessment are urgently needed. Recently, serum biomarkers have made a great progress and become a focus in IBD study because they are non-invasive, convenient, and relatively inexpensive than are markers in biopsy tissue, stool, breath, and other body fluids. Aims: To review the available data on serological biomarkers for IBD. Methods: We searched PubMed using predefined key words on relevant literatures of serum biomarkers regarding diagnosis, evaluation of therapeutic efficacy, surveillance of disease activity, and assessment of prognosis for IBD. Results: We reviewed serological biomarkers that are well-established and widely used (e.g., C-reactive protein), newly discovered biomarkers (e.g., cytokines, antibodies, and non-coding RNAs), and also recently advancements in serological biomarkers (e.g., metabolomics and proteomics) that are used in different aspects of IBD management. Conclusions: With such a wealth of researches, to date, there are still no ideal serum biomarkers for IBD. Serum profiling and non-coding RNAs are just starting to blossom but reveal great promise for future clinical practice. Combining different biomarkers can be valuable in improving performance of disease evaluation.

show abstract

Section: Vitamin Dmentioning

confidence: 99%

Serum Biomarkers for Inflammatory Bowel Disease

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…70 Although VD is thought to be associated with nutritional status in CD patients, there have been few studies on the association between the serum VD level and nutritional status in CD patients. [71][72][73][74] A study by Prieto JMI et al illustrated a similar relationship between low weight and micronutrient deficiency in CD patients who were underweight and deficient in micronutrients. 72 In summary, we found that VD was associated with both nutritional deficits and inflammation, and that nutritional deficit was associated with inflammation, suggesting that VD supplementation may play an anti-inflammatory role, improve nutritional status and thus improve prognosis.…”

Section: Discussionmentioning

confidence: 85%

“…Treatment of monocytes with 1,25(OH)2D was found to inhibit lipopolysaccharide (LPS)‐induced p38 phosphorylation as well as IL‐6 and TNF‐ α production, thus preventing excessive activation of pro‐inflammatory responses 70 . Although VD is thought to be associated with nutritional status in CD patients, there have been few studies on the association between the serum VD level and nutritional status in CD patients 71–74 . A study by Prieto JMI et al illustrated a similar relationship between low weight and micronutrient deficiency in CD patients who were underweight and deficient in micronutrients 72 .…”

Section: Discussionmentioning

confidence: 99%

Vitamin D levels in the assessment of Crohn's disease activity and their relation to nutritional status and inflammation

Zheng

et al. 2023

J Human Nutrition Diet

View full text Add to dashboard Cite

Background Crohn's disease (CD) is frequently associated with malnutrition, inflammation and a deficiency of vitamin D (VD) with the relationships between these symptoms being poorly defined. VD is a modulator of the immune system and is associated with the onset of CD and disease activity. The level of serum VD may have potential in the assessment of CD activity. This study aimed to evaluate the relationships between VD, nutritional status and inflammation, and to identify more accurate VD thresholds. Methods The study included 76 outpatients with CD diagnosed between October 2018 and October 2020 and 76 healthy volunteers. Levels of serum 25(OH)D and nutritional indicators, as well as biochemical and disease activity assessments, were conducted. Results Patients with CD and healthy participants were found to differ significantly in their 25(OH)D levels as well in levels of nutritional and inflammatory indicators. The optimal VD cut‐off value was found to be 46.81 nmol/L for CD development and 35.32 nmol/L for disease activity. Levels of 25(OH)D were correlated with both nutritional status and inflammation. Conclusions The VD level is likely to be a useful additional tool in the evaluation of CD patients and predicting the disease activity and clinical response. The VD level may relate both to the nutritional status and levels of inflammation in CD patients, and disease progression.

show abstract

“…Circulating noncoding RNAs, including microRNAs (miRNAs) and long ncRNAs (lncRNAs), also play a role in IBD, and the analysis of miRNAs might help monitor disease activity and stricture phenotypes[ 32 ]. Other newly emerging biomarkers for disease progression risk and activity include cathelicidin[ 40 ], trefoil factor 3[ 41 ], and 25-hydroxyvitamin D3[ 42 ]. Several extracellular matrix (ECM) components and growth factors are important biomarkers indicating intestinal fibrosis and stenosis[ 32 ].…”

Section: Biomarkersmentioning

confidence: 99%

Advancing the precision management of inflammatory bowel disease in the era of omics approaches and new technology

Liu¹,

Tang²,

Zhou³

et al. 2023

World J Gastroenterol

View full text Add to dashboard Cite

There is great heterogeneity among inflammatory bowel disease (IBD) patients in terms of pathogenesis, clinical manifestation, response to treatment, and prognosis, which requires the individualized and precision management of patients. Many studies have focused on prediction biomarkers and models for assessing IBD disease type, activity, severity, and prognosis. During the era of biologics, how to predict the response and side effects of patients to different treatments and how to quickly recognize the loss of response have also become important topics. Multiomics is a promising area for investigating the complex network of IBD pathogenesis. Integrating numerous amounts of data requires the use of artificial intelligence.

show abstract

A New Model Based on 25-Hydroxyvitamin D3 for Predicting Active Crohn’s Disease in Chinese Patients

Cited by 9 publications

References 39 publications

Serum Biomarkers for Inflammatory Bowel Disease

Serum Biomarkers for Inflammatory Bowel Disease

Vitamin D levels in the assessment of Crohn's disease activity and their relation to nutritional status and inflammation

Advancing the precision management of inflammatory bowel disease in the era of omics approaches and new technology

Contact Info

Product

Resources

About